These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. An overview on biological mechanisms of PPARs. Kota BP; Huang TH; Roufogalis BD Pharmacol Res; 2005 Feb; 51(2):85-94. PubMed ID: 15629253 [TBL] [Abstract][Full Text] [Related]
6. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. Mahindroo N; Peng YH; Lin CH; Tan UK; Prakash E; Lien TW; Lu IL; Lee HJ; Hsu JT; Chen X; Liao CC; Lyu PC; Chao YS; Wu SY; Hsieh HP J Med Chem; 2006 Oct; 49(21):6421-4. PubMed ID: 17034149 [TBL] [Abstract][Full Text] [Related]
7. Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation. Wei ZL; Petukhov PA; Bizik F; Teixeira JC; Mercola M; Volpe EA; Glazer RI; Willson TM; Kozikowski AP J Am Chem Soc; 2004 Dec; 126(51):16714-5. PubMed ID: 15612696 [TBL] [Abstract][Full Text] [Related]
8. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. Mansour M Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239 [TBL] [Abstract][Full Text] [Related]
9. Biological evaluation and structural insights for design of subtype-selective peroxisome proliferator activated receptor-α (PPAR-α) agonists. Gangwal RP; Damre MV; Das NR; Sharma SS; Sangamwar AT Bioorg Med Chem Lett; 2015 Jan; 25(2):270-5. PubMed ID: 25491112 [TBL] [Abstract][Full Text] [Related]
10. PPARs as therapeutic targets in cardiovascular disease. van Bilsen M; van Nieuwenhoven FA Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists. Kaserer T; Obermoser V; Weninger A; Gust R; Schuster D Eur J Med Chem; 2016 Nov; 124():49-62. PubMed ID: 27560282 [TBL] [Abstract][Full Text] [Related]
12. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Mirza AZ; Althagafi II; Shamshad H Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829 [TBL] [Abstract][Full Text] [Related]
13. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Salam NK; Huang TH; Kota BP; Kim MS; Li Y; Hibbs DE Chem Biol Drug Des; 2008 Jan; 71(1):57-70. PubMed ID: 18086153 [TBL] [Abstract][Full Text] [Related]
14. Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening. Sundriyal S; Bharatam PV Eur J Med Chem; 2009 Sep; 44(9):3488-95. PubMed ID: 19268404 [TBL] [Abstract][Full Text] [Related]
15. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease. Bisgaier CL; Oniciu DC; Srivastava RAK J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036 [TBL] [Abstract][Full Text] [Related]